Advertisement LCS Group to commercialize '813 patent and '249 application for binge eating disorder - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

LCS Group to commercialize ‘813 patent and ‘249 application for binge eating disorder

LCS Group has announced its exclusive license from Lucerne Biosciences to commercialize US Patent No. 8,318,813 and U.S. Patent Application No. 14/464,249, both titled "Method of Treating Binge Eating Disorder" ("BED").

LCS Group’s exclusive license is part of a unique strategic collaboration with the intellectual property’s owner, Lucerne Biosciences, with further details of the collaboration soon to be announced.

LCS Group’s commercialization of the ‘813 Patent and ‘249 Application is planned through Shire US Inc.’s national marketing campaign of the drug lisdexamfetamine dimesylate ("LDX") to treat BED.

The ‘813 Patent’s and ‘249 Application’s claims both encompass the use of LDX to treat BED, with the ‘249 Application featuring methods that include "informing a patient that LDX is therapeutically effective for treating BED," as by "a flyer, an advertisement, a package insert for a pharmaceutical product, printed labeling, an internet website, an internet pop-up window, or information on a compact disk, DVD, or an audio recording."

"This exclusive license to commercialize Lucerne Biosciences’ intellectual property for a drug recently approved by the FDA to treat BED and currently marketed by Shire for that purpose is an important step forward in bringing much needed public attention to the proper diagnosis and treatment of BED.

"Public misconceptions on diagnosing and treating of BED have abounded, even among healthcare professionals and the pharmaceutical industry. LCS Group has taken unprecedented actions to publicly clarify them through its novel commercialization platform, collaboration with Lucerne Biosciences, and even Shire’s own solid marketing efforts. With LDX the first and currently only FDA approved treatment for moderate to severe adult BED, there’s no better time than now to educate the public-at-large on how to properly diagnose and treat this serious disorder," said Louis Sanfilippo, M.D., CEO of LCS Group.